Logo 1200x628.jpg
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
12. Dezember 2024 07:00 ET | CytoSorbents
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
Logo 1200x628.jpg
CytoSorbents Announces Rights Offering
09. Dezember 2024 07:00 ET | CytoSorbents
CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024
Logo 1200x628.jpg
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
26. November 2024 07:00 ET | CytoSorbents
CytoSorbents to Participate in the Piper Sandler 36th Annual Healthcare Conference. Management holding one-on-one meetings with investors
Logo 1200x628.jpg
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
11. November 2024 07:30 ET | CytoSorbents; Converge Biotech
CytoSorbents and Converge Biotech Partner In India to Expand CytoSorb Blood Purification Availability to Treat Sepsis and Other Deadly Conditions
Logo 1200x628.jpg
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07. November 2024 16:05 ET | CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Logo 1200x628.jpg
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22. Oktober 2024 07:00 ET | CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
Logo 1200x628.jpg
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
17. Oktober 2024 07:00 ET | CytoSorbents
CytoSorbents to Announce Q3 2024 Financial and Operating Results on November 7, 2024
Logo 1200x628.jpg
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
27. August 2024 07:00 ET | CytoSorbents
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Logo 1200x628.jpg
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
13. August 2024 16:19 ET | CytoSorbents
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by...
Logo 1200x628.jpg
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
13. August 2024 16:18 ET | CytoSorbents
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...